Director Jason Aryeh filed a Form 4 with the SEC on November 6, 2026, disclosing a sale of Ligand Pharmaceuticals common stock on November 4, 2026.

Key Highlights

  • Shares sold: Jason Aryeh disposed of 282 shares of Ligand Pharmaceuticals common stock on November 4, 2026.
  • Sale price: The shares were sold at $319.99 each, according to the filing.
  • Direct ownership after transaction: Following the sale, Aryeh directly held 108,476 shares of common stock.
  • Indirect ownership: An additional 8,000 shares are held indirectly through funds managed by JALAA Equities, LP, JLV Investments, LP, and affiliates.
  • Role: The filing identifies Aryeh as a director of Ligand Pharmaceuticals Inc (NASDAQ:LGND).
  • Transaction code: The disposal was recorded under transaction code S (open-market sale).

Aryeh's November 4 Share Sale and Beneficial Ownership at Ligand Pharmaceuticals

According to the Form 4 filed on November 6, 2026, Jason Aryeh, a director of Ligand Pharmaceuticals Inc (NASDAQ:LGND), sold 282 shares of the company's common stock on November 4, 2026, at a price of $319.99 per share. The transaction was coded "S," indicating an open-market sale. The filing was signed by Andrew Reardon as attorney-in-fact for Jason Aryeh.

Following the reported transaction, the filing states that Aryeh directly held 108,476 shares of Ligand Pharmaceuticals common stock. In addition, 8,000 shares are reported as indirectly held. The filing's footnote explains that these indirectly held shares are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP, and affiliates. Aryeh serves as the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. The filing notes that "by reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds."

No derivative securities transactions were reported in Table II of this filing. The Form 4 was filed by one reporting person and indicates this is not an amendment to a prior filing.

What Was Disclosed

Director Jason Aryeh disclosed the sale of 282 shares of Ligand Pharmaceuticals common stock at $319.99 on November 4, 2026, leaving him with direct beneficial ownership of 108,476 shares and indirect ownership of 8,000 shares through affiliated funds.